# Concurrent Radiochemotherapy Plus Anlotinib for Locally Advanced Cervical Cancer

> **NCT04772001** · NA · UNKNOWN · sponsor: **Zhongnan Hospital** · enrollment: 53 (estimated)

## Conditions studied

- Uterine Cervical Neoplasms
- Chemoradiotherapy
- Angiogenesis

## Interventions

- **DRUG:** Hydrochloride anlotinib
- **DRUG:** cis Platinum/carboplatin
- **RADIATION:** External beam radiotherapy and brachytherapy

## Key facts

- **NCT ID:** NCT04772001
- **Lead sponsor:** Zhongnan Hospital
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-03-12
- **Primary completion:** 2025-10
- **Final completion:** 2026-01
- **Target enrollment:** 53 (ESTIMATED)
- **Last updated:** 2022-05-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04772001

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04772001, "Concurrent Radiochemotherapy Plus Anlotinib for Locally Advanced Cervical Cancer". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04772001. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*